NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Overall, NXP800 has antitumor activity against treatment-resistant prostate cancer models, including molecular subtypes with limited treatment options, supporting its consideration for prostate cancer-specific clinical development.
Authors
- Paul Workman (ORCID: https://orcid.org/0000-0003-1659-3034)
- Jonathan Welti (ORCID: https://orcid.org/0000-0002-9433-8138)
- Matthew D. Cheeseman (ORCID: https://orcid.org/0000-0003-1121-6985)
- Jyoti S. Choudhary (ORCID: https://orcid.org/0000-0003-0881-5477)
- Veronica Gil (ORCID: https://orcid.org/0000-0002-4562-869X)
- Bora Gürel (ORCID: https://orcid.org/0000-0002-5018-8078)
- Amandeep Bhamra (ORCID: https://orcid.org/0000-0002-7464-6387)
- Antje Neeb (ORCID: https://orcid.org/0000-0002-6516-2938)
- Dapei Li (ORCID: https://orcid.org/0000-0003-2743-8435)
- Ilona Bernett
- Juan M. Jiménez‐Vacas (ORCID: https://orcid.org/0000-0003-4391-3726)
- Udai Banerji (ORCID: https://orcid.org/0000-0003-1503-3123)
- Ines Figueiredo (ORCID: https://orcid.org/0009-0007-2754-5608)
- Paul Andrew Clarke (ORCID: https://orcid.org/0000-0001-9342-1290)
- Mateus Crespo (ORCID: https://orcid.org/0000-0003-4043-8296)
- Denisa Bogdan (ORCID: https://orcid.org/0000-0002-3017-4832)
- Marissa Powers (ORCID: https://orcid.org/0000-0003-0775-4908)
- Jan Rekowski (ORCID: https://orcid.org/0000-0002-5207-3864)
- Amanda Swain (ORCID: https://orcid.org/0000-0001-8666-1608)
- Nina Tunariu (ORCID: https://orcid.org/0000-0001-6656-3699)
- Robert te Poele (ORCID: https://orcid.org/0009-0001-3596-6572)
- Susana Miranda (ORCID: https://orcid.org/0000-0002-5936-2706)
- Wei Yuan (ORCID: https://orcid.org/0000-0001-8004-1846)
- Ana Ferreira (ORCID: https://orcid.org/0000-0002-7844-2760)
- N. Chessum (ORCID: https://orcid.org/0000-0003-4125-320X)
- Ruth Riisnaes (ORCID: https://orcid.org/0000-0002-8924-302X)
- Peter S. Nelson (ORCID: https://orcid.org/0000-0002-5451-5726)
- Adam Sharp (ORCID: https://orcid.org/0000-0002-3740-1612)
- Claudia Bertan (ORCID: https://orcid.org/0009-0009-2688-9067)
- Johann Sebastian De Bono (ORCID: https://orcid.org/0000-0002-2034-595X)
- Lorenzo Buroni (ORCID: https://orcid.org/0000-0003-1999-4028)
- Theodoros I. Roumeliotis (ORCID: https://orcid.org/0000-0002-3354-5643)
- Elisa Pasqua (ORCID: https://orcid.org/0000-0002-7966-4672)
- Ilsa M. Coleman (ORCID: https://orcid.org/0000-0002-1483-7202)
- Jian Ning (ORCID: https://orcid.org/0009-0002-0683-1924)
- Suzanne Carreira (ORCID: https://orcid.org/0000-0002-5077-5379)
- Keith Jones (ORCID: https://orcid.org/0000-0002-9440-4094)
- Wanting Zeng (ORCID: https://orcid.org/0000-0002-4101-1502)
- Kate Liodaki (ORCID: https://orcid.org/0009-0001-9500-8093)
- Franziska Weigl (ORCID: https://orcid.org/0000-0002-6381-2829)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- University of Washington (US)
- Cancer Research UK (GB)
- Fred Hutch Cancer Center (US)
- Royal Marsden Hospital (GB)
- Boehringer Ingelheim (Egypt) (EG)
- Seattle University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2386
- Citations
- 7
- Primary Topic
- Heat shock proteins research
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Medical Research Council